Disease-processes experienced by critically ill patients commonly cause unique
pharmacokinetic (PK) changes, that may result in drug concentrations that are either …

The pharmacokinetics of beta-lactam antibiotics in intensive care patients may be profoundly
altered due to the dynamic, unpredictable pathophysiological changes that occur in critical …

The extreme pharmacokinetic behaviour of drugs sometimes observed in critically ill patients
poses a significant threat to the achievement of optimal antibiotic treatment outcomes. Scant …

Beta-lactams (BL) are the first line agents for the antibiotic management of critically ill
patients with sepsis or septic shock. BL are hydrophilic antibiotics particularly subject to …

Beta-lactam antibiotics remain one of the most preferred groups of antibiotics in critical care
due to their excellent safety profiles and their activity against a wide spectrum of pathogens …

Critically ill patients have increased variability in beta-lactam antibiotic (beta-lactam)
exposure due to alterations in their volume of distribution and elimination. Therapeutic drug …

Bacterial infections are potentially life-threatening diseases requiring effective antibiotic
treatment right from the outset to achieve a favourable prognosis. Therapeutic success …

Introduction Individualizing antibiotic therapy is paramount to improve clinical outcomes
while minimizing the risk of toxicity and antimicrobial therapy. β-lactam antibiotics are …

In beta-lactam therapy, investigation of the pharmacokinetic-pharmacodynamic (PK-PD)
relationship has provided surrogate makers to predict clinical outcome. This study was …

OBJECTIVE: β-lactams are the cornerstone of empiric and targeted antibiotic therapy for
critically ill patients. Recently, there have been calls to use β-lactam therapeutic drug …